Will IOVA rise till 2025

**Iovance Biotherapeutics (IOVA) is poised for a potential rise in 2025**, driven by several key factors:

1. **Recent Surge and Market Sentiment**: IOVA saw a significant 23% rise in pre-market trading on July 23, 2025, reflecting increased investor interest and optimism. This surge was fueled by a mix of growing buzz around the company's pipeline and speculation about regulatory progress.
2. **Technical Breakout and Short Squeeze Potential**: The stock's recent rally of 32% on July 24, 2025, can be attributed to a technical breakout, which often triggers a wave of buying, including short covering. With approximately 34.5% of its float sold short, IOVA has the potential for a classic short squeeze play.
3. **Strategic Appointments and Financial Management**: The appointment of Corleen Roche as Chief Financial Officer is expected to strengthen the company's financial management and operational efficiency, which should bolster investor confidence.
4. **Pipeline and Regulatory Progress**: Iovance's newly approved Amtagvi has cleared the runway for market expansion, and the company is targeting significant revenue and gross margin goals. The FDA rejection of a competing treatment has also opened up opportunities for Iovance to gain market share.
5. **Analyst Ratings and Price Targets**: Despite some downgrades, analysts remain bullish on Iovance, with price targets indicating confidence in the company's long-term potential. Geulah Livshits from Chardan Capital has set a price target of $25 for IOVA, suggesting a belief in the company's growth prospects.

In conclusion, while IOVA's stock price may experience fluctuations in the short term, the company's strategic moves, pipeline progress, and bullish analyst ratings suggest that it could experience growth in 2025. Investors should monitor the company's performance closely, particularly its ability to execute on its strategic plans and meet financial targets.